FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1508752722> ?p ?o ?g. }

• W1508752722 endingPage "421" @default.
• W1508752722 startingPage "412" @default.
• W1508752722 abstract "Background Conventional systemic therapies for plaque psoriasis have not fully met the needs of patients, and although current biologic treatments are generally well tolerated, concerns exist with respect to long-term safety. Interleukin (IL)-17A is believed to be an important effector cytokine in the pathogenesis of psoriasis and is produced by Th17 cells, a class of helper T cells that act outside the established Th1/Th2 paradigm for regulation of innate and adaptive immunity. Objectives To assess the efficacy and safety of different doses of secukinumab, a fully human anti-IL-17A IgG1κ monoclonal antibody, in patients with moderate-to-severe plaque psoriasis. Methods Patients (n = 125) were randomized 1 : 1 : 1 : 1 : 1 to receive subcutaneous doses of placebo (n = 22) or secukinumab [1 × 25 mg (n = 29), 3 × 25 mg (n = 26), 3 × 75 mg (n = 21) or 3 × 150 mg (n = 27)] at weeks 0, 4 and 8. After the 12-week treatment period, patients entered a follow-up period of 24 weeks. The primary efficacy outcome was at least 75% improvement from baseline in the Psoriasis Area and Severity Index score (PASI 75); secondary outcomes included the Investigator’s Global Assessment (IGA) and PASI 90 and 50 response rates. Results After 12 weeks of treatment, secukinumab 3 × 150 mg and 3 × 75 mg resulted in significantly higher PASI 75 response rates vs. placebo (82% and 57% vs. 9%; P < 0·001 and P = 0·002, respectively). Higher PASI 75 response rates compared with placebo were maintained throughout the follow-up period with these dosages [week 36, 26% (n = 7) and 19% (n = 4) vs. 4% (n = 1), respectively], with a gradual decline of PASI 75 response over time after the dosing period. IGA response rates were significantly higher in the 3 × 150 mg group vs. placebo at week 12 (48% vs. 9%; P = 0·005) and were consistently higher for the 3 × 150 mg and 3 × 75 mg groups vs. placebo at all time points from week 4 onward. The PASI 90 response rate was significantly higher in the 3 × 150 mg group vs. placebo (52% vs. 5%) at week 12 and remained higher during the follow-up period. Secukinumab was well tolerated. Two cases of neutropenia (≤ grade 2) were reported in the 3 × 150 mg cohort. Conclusions Treatment with subcutaneous secukinumab 3 × 75 mg and 3 × 150 mg met the primary outcome of PASI 75 response achievement after 12 weeks, demonstrating efficacy in moderate-to-severe psoriasis." @default.
• W1508752722 created "2016-06-24" @default.
• W1508752722 creator A5007388960 @default.
• W1508752722 creator A5008286260 @default.
• W1508752722 creator A5016651473 @default.
• W1508752722 creator A5023480711 @default.
• W1508752722 creator A5028006147 @default.
• W1508752722 creator A5035039792 @default.
• W1508752722 creator A5045741722 @default.
• W1508752722 creator A5061849637 @default.
• W1508752722 creator A5089494697 @default.
• W1508752722 creator A5090082837 @default.
• W1508752722 date "2013-01-18" @default.
• W1508752722 modified "2023-10-13" @default.
• W1508752722 title "Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study" @default.
• W1508752722 cites W1532206496 @default.
• W1508752722 cites W1974560684 @default.
• W1508752722 cites W1987628377 @default.
• W1508752722 cites W1993273784 @default.
• W1508752722 cites W1994704539 @default.
• W1508752722 cites W2040041622 @default.
• W1508752722 cites W2067327580 @default.
• W1508752722 cites W2080090843 @default.
• W1508752722 cites W2103018315 @default.
• W1508752722 cites W2107235439 @default.
• W1508752722 cites W2112128505 @default.
• W1508752722 cites W2127834887 @default.
• W1508752722 cites W2159513688 @default.
• W1508752722 cites W2322390243 @default.
• W1508752722 cites W2561759163 @default.
• W1508752722 doi "https://doi.org/10.1111/bjd.12110" @default.
• W1508752722 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23106107" @default.
• W1508752722 hasPublicationYear "2013" @default.
• W1508752722 type Work @default.
• W1508752722 sameAs 1508752722 @default.
• W1508752722 citedByCount "315" @default.
• W1508752722 countsByYear W15087527222013 @default.
• W1508752722 countsByYear W15087527222014 @default.
• W1508752722 countsByYear W15087527222015 @default.
• W1508752722 countsByYear W15087527222016 @default.
• W1508752722 countsByYear W15087527222017 @default.
• W1508752722 countsByYear W15087527222018 @default.
• W1508752722 countsByYear W15087527222019 @default.
• W1508752722 countsByYear W15087527222020 @default.
• W1508752722 countsByYear W15087527222021 @default.
• W1508752722 countsByYear W15087527222022 @default.
• W1508752722 countsByYear W15087527222023 @default.
• W1508752722 crossrefType "journal-article" @default.
• W1508752722 hasAuthorship W1508752722A5007388960 @default.
• W1508752722 hasAuthorship W1508752722A5008286260 @default.
• W1508752722 hasAuthorship W1508752722A5016651473 @default.
• W1508752722 hasAuthorship W1508752722A5023480711 @default.
• W1508752722 hasAuthorship W1508752722A5028006147 @default.
• W1508752722 hasAuthorship W1508752722A5035039792 @default.
• W1508752722 hasAuthorship W1508752722A5045741722 @default.
• W1508752722 hasAuthorship W1508752722A5061849637 @default.
• W1508752722 hasAuthorship W1508752722A5089494697 @default.
• W1508752722 hasAuthorship W1508752722A5090082837 @default.
• W1508752722 hasBestOaLocation W15087527221 @default.
• W1508752722 hasConcept C126322002 @default.
• W1508752722 hasConcept C142724271 @default.
• W1508752722 hasConcept C168563851 @default.
• W1508752722 hasConcept C197934379 @default.
• W1508752722 hasConcept C203014093 @default.
• W1508752722 hasConcept C204787440 @default.
• W1508752722 hasConcept C27081682 @default.
• W1508752722 hasConcept C2776260265 @default.
• W1508752722 hasConcept C2777011040 @default.
• W1508752722 hasConcept C2778690821 @default.
• W1508752722 hasConcept C2779384505 @default.
• W1508752722 hasConcept C2779786854 @default.
• W1508752722 hasConcept C2780564577 @default.
• W1508752722 hasConcept C2780699399 @default.
• W1508752722 hasConcept C3020604521 @default.
• W1508752722 hasConcept C47348012 @default.
• W1508752722 hasConcept C535046627 @default.
• W1508752722 hasConcept C71924100 @default.
• W1508752722 hasConcept C90924648 @default.
• W1508752722 hasConceptScore W1508752722C126322002 @default.
• W1508752722 hasConceptScore W1508752722C142724271 @default.
• W1508752722 hasConceptScore W1508752722C168563851 @default.
• W1508752722 hasConceptScore W1508752722C197934379 @default.
• W1508752722 hasConceptScore W1508752722C203014093 @default.
• W1508752722 hasConceptScore W1508752722C204787440 @default.
• W1508752722 hasConceptScore W1508752722C27081682 @default.
• W1508752722 hasConceptScore W1508752722C2776260265 @default.
• W1508752722 hasConceptScore W1508752722C2777011040 @default.
• W1508752722 hasConceptScore W1508752722C2778690821 @default.
• W1508752722 hasConceptScore W1508752722C2779384505 @default.
• W1508752722 hasConceptScore W1508752722C2779786854 @default.
• W1508752722 hasConceptScore W1508752722C2780564577 @default.
• W1508752722 hasConceptScore W1508752722C2780699399 @default.
• W1508752722 hasConceptScore W1508752722C3020604521 @default.
• W1508752722 hasConceptScore W1508752722C47348012 @default.
• W1508752722 hasConceptScore W1508752722C535046627 @default.
• W1508752722 hasConceptScore W1508752722C71924100 @default.
• W1508752722 hasConceptScore W1508752722C90924648 @default.
• W1508752722 hasIssue "2" @default.

• next